- Acquired by Quoin Pharmaceuticals, Nov 2021
- Raised $908k grant, Jun 2016
- Raised $2M funding round, Feb 2016
About
Cellect Biotechnology develops solutions for immune system regeneration. Its platform technology is based on the idea that the functional properties of stem cells, rather than their appearance, should be used for their identification, selection, and utilization. The companys first product is designed to harness the critical function of sensitivity to specific apoptosis-inducing agents. These molecules induce apoptosis in mature cells while sparing stem cells, and this differential sensitivity is used to dramatically improve the outcome of bone marrow transplants. By achieving selectivity, specificity, and decreased toxicity, Cellect Biotechnology envisions its products becoming an integral and essential part of bone marrow transplants and being integrated into many aspects of regenerative medicine. In January 2018, Cellect Biotechnology signed an agreement with Hadassah Medical Center to conduct a clinical trial of the companys ApoGraft. In April 2018, the company announced it had completed POC testing for the first scalable production of ApoTainer, which is designed to replace the highly complex and expensive procedures currently used by laboratories (e.g. bone marrow transplants), providing a significantly more effective process at a fraction of the time and cost.
Funding history · 2 rounds · $24.3M total
Q&A
- What is Cellect Biotechnology's primary focus?
- Cellect Biotechnology develops solutions for immune system regeneration, utilizing a platform technology based on identifying, selecting, and utilizing stem cells by their functional properties rather than appearance.
- When was Cellect Biotechnology acquired and by whom?
- Cellect Biotechnology was acquired by Quoin Pharmaceuticals in November 2021.
- How many employees does Cellect Biotechnology have?
- Cellect Biotechnology has 11-50 employees.
- Who are the co-founders of Cellect Biotechnology?
- The co-founders of Cellect Biotechnology are Nuriel Chirich-Kasbian, who serves as Co-founder & Chairman, and Shai Yarkoni, who is the Co-founder & CEO.
- What was Cellect Biotechnology's total funding raised?
- Cellect Biotechnology raised a total of $24,257,523.
- Which investors participated in Cellect Biotechnology's funding rounds?
- Cellect Biotechnology received funding from Shrem-Zilberman Group and BIRD Foundation.
- What was the latest funding round for Cellect Biotechnology?
- The latest funding round for Cellect Biotechnology was a Grant in June 2016, amounting to $907,523.
- What is the status of Cellect Biotechnology?
- Cellect Biotechnology is currently listed as acquired and inactive due to its acquisition by Quoin Pharmaceuticals in November 2021.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2011-6 |
|---|---|
| Employees (exact) | 19 |
| Status reason | Acquired (Inactive) by Quoin Pharmaceuticals on Nov 2021 - closed due to acquisition |
Acquisitions & public offerings
Acquired by Quoin Pharmaceuticals 2021-11
Radar intelligence
Patents
| EPO | 6 |
|---|